◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Dr. Reddy’s Laboratories Ltd ADR (RDY) Net Income 2007–TTM

Name: Dr. Reddy’s Laboratories Ltd ADR (RDY) net income history 2007-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-07-29

Dr. Reddy’s Laboratories Ltd ADR annual net income for fiscal TTM was ₹33.2 billion, a decrease of 26.4% from ₹45.1 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

RDY Annual Net Income

Net Income (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31
Net Income	₹33.2B	₹45.1B	₹56.5B	₹55.7B	₹45.1B	₹23.6B	₹232M	₹19.5B	₹18.8B	₹9.8B	₹12.0B	₹20.0B	₹22.2B	₹21.5B	₹16.8B	₹14.3B	₹11.0B	₹1.1B	(₹5.2B)	₹4.7B	₹9.3B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RDY Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Net Income	₹4.5B	₹2.2B	₹12.1B	₹14.4B	₹14.2B	₹15.9B	₹14.1B	₹12.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

UTHR Net Income — United Therapeutics Corporation
NBIX Net Income — Neurocrine Biosciences Inc
ELAN Net Income — Elanco Animal Health
ALKS Net Income — Alkermes Plc
HIMS Net Income — Hims Hers Health Inc

More RDY metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All RDY financial statements → Interactive RDY charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.